Liquidia Corp Files Q1 2025 10-Q
Ticker: LQDA · Form: 10-Q · Filed: May 8, 2025
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Liquidia's Q1 2025 10-Q is in: check retained earnings & paid-in capital for financial health.
AI Summary
Liquidia Corporation filed a 10-Q for the period ending March 31, 2025. The company, based in Morrisville, NC, operates in the pharmaceutical preparations sector. Key financial data points include retained earnings and additional paid-in capital as of March 31, 2025, and other comparative dates.
Why It Matters
This filing provides investors with an update on Liquidia's financial position and performance for the first quarter of 2025, crucial for understanding the company's operational health and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Liquidia faces inherent risks related to drug development, regulatory approvals, and market competition, which are not detailed in this specific filing but are typical for the industry.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-05-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations.)
Key Players & Entities
- Liquidia Corp (company) — Filer of the 10-Q
- Morrisville, NC (location) — Company's business address
- March 31, 2025 (date) — End of the reporting period
- 20250331 (date) — Conformed period of report
- 0001819576 (company) — Central Index Key for Liquidia Corp
FAQ
What is the total revenue for Liquidia Corp for the quarter ending March 31, 2025?
The provided filing excerpt does not contain specific revenue figures for the quarter ending March 31, 2025. It primarily focuses on header information and financial statement element dates.
What were Liquidia Corp's net earnings or losses for the period?
The excerpt does not detail net earnings or losses for the period ending March 31, 2025. It lists dates for retained earnings and additional paid-in capital.
Has Liquidia Corp announced any new product developments or clinical trial updates in this filing?
This excerpt of the 10-Q filing does not include information on new product developments or clinical trial updates; it focuses on financial reporting metadata.
What is the company's cash and cash equivalents balance as of March 31, 2025?
Specific figures for cash and cash equivalents as of March 31, 2025, are not present in this provided header information.
What are the key changes in Liquidia Corp's balance sheet items like Retained Earnings or Additional Paid-In Capital compared to the previous year?
While the filing indicates the dates for Retained Earnings and Additional Paid-In Capital for March 31, 2025, and comparative periods (e.g., 2024-12-31, 2024-03-31, 2023-12-31), the actual values and year-over-year changes are not detailed in this excerpt.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Liquidia Corp (LQDA).